Advertisement

Advertisement

ADCT Stock Latest News

ADC Therapeutics Announces Major Financial Restructuring Initiatives

Company AnnouncementsADC Therapeutics Announces Major Financial Restructuring Initiatives

ADC Therapeutics announces comprehensive strategic financial restructuring

PremiumThe Fly

ADC Therapeutics announces comprehensive strategic financial restructuring

5d ago

ADC Therapeutics Balances Earnings Gains With Trial Risks

PremiumCompany Announcements

ADC Therapeutics Balances Earnings Gains With Trial Risks

2M ago

ADC Therapeutics price target lowered to $5 from $10 at Guggenheim

PremiumThe Fly

ADC Therapeutics price target lowered to $5 from $10 at Guggenheim

2M ago

ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year

PremiumThe Fly

ADC Therapeutics reports Q2 adjusted EPS (11c) vs. (25c) last year

2M ago

ADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path

PremiumCompany AnnouncementsADC Therapeutics Reports Q2 2026 Results, Reassesses ZYNLONTA Path

2M ago

ADCT Upcoming Earnings Report: What to Expect?

Pre-Earnings

ADCT Upcoming Earnings Report: What to Expect?

2M ago

ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors

Company Announcements

ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors

3M ago

ADC Therapeutics Grants One-Time Retention Awards to Executives

PremiumCompany Announcements

ADC Therapeutics Grants One-Time Retention Awards to Executives

3M ago

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

PremiumThe Fly

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

3M ago

ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization

PremiumCompany Announcements

ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization

4M ago

ADC Therapeutics to reduce workforce by 17% globally

PremiumThe Fly

ADC Therapeutics to reduce workforce by 17% globally

4M ago

ADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

PremiumThe FlyADC Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

4M ago

ADC Therapeutics price target lowered to $5 from $8 at Stephens

The Fly

ADC Therapeutics price target lowered to $5 from $8 at Stephens

4M ago

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

The Fly

ADC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

4M ago

ADC Therapeutics announces positive ZYNLONTA Phase 3 results

PremiumCompany Announcements

ADC Therapeutics announces positive ZYNLONTA Phase 3 results

4M ago

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

PremiumThe Fly

ADC Therapeutics’ Zynlonta combination shows survival efficacy in DLBCL

4M ago

ADC Therapeutics Shareholders Back Governance and Capital Changes

PremiumCompany Announcements

ADC Therapeutics Shareholders Back Governance and Capital Changes

4M ago

Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8

PremiumRatings

Buy Rating Reiterated on Strong Execution and Pipeline Catalysts; 12-Month Price Target Maintained at $8

5M ago

ADC Therapeutics Balances Solid Quarter With Trial Risk

PremiumCompany AnnouncementsADC Therapeutics Balances Solid Quarter With Trial Risk

5M ago

ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

The Fly

ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

5M ago

ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet

Pre-Earnings

ADC Therapeutics Ltd (ADCT) Q1 Earnings Cheat Sheet

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >